WNT9A and colorectal carcinoma: Dose titration studies demonstrated that recombinant Wnt9A protein suppressed the proliferation of CRC proliferation in a concentration dependent manner which, at 500 ng/mL, led to proliferation inhibition of 24% (p < 0.001, Figure 5A).